Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2007-07-23
2010-11-16
Rawlings, Stephen L (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S133100, C424S145100, C424S158100, C530S300000, C530S350000, C530S387100, C530S388240, C530S389200, C435S375000
Reexamination Certificate
active
07833526
ABSTRACT:
The present invention relates to the discovery that relaxin is associated with the development or maturation of body tissues. Knockouts of the gene encoding relaxin result in various abnormalities in the development of various tissues. The present invention provides methods of modulating apoptosis by administering a relaxin agonist or antagonist to a subject.
REFERENCES:
patent: 4758516 (1988-07-01), Hudson et al.
patent: 4835251 (1989-05-01), Burnier et al.
patent: 4889818 (1989-12-01), Gelfand et al.
patent: 5023321 (1991-06-01), Hudson et al.
patent: 5108919 (1992-04-01), Liu et al.
patent: 5166191 (1992-11-01), Cronin et al.
patent: 5179195 (1993-01-01), Hudson et al.
patent: 5464756 (1995-11-01), Henner et al.
patent: 5612051 (1997-03-01), Yue
patent: 5707642 (1998-01-01), Yue
patent: 5753623 (1998-05-01), Amento et al.
patent: 5795807 (1998-08-01), Gardner et al.
patent: 5811395 (1998-09-01), Schwabe et al.
patent: 5863552 (1999-01-01), Yue
patent: 5945402 (1999-08-01), Cipolla et al.
patent: 5965405 (1999-10-01), Winter et al.
patent: 6048544 (2000-04-01), Yue
patent: 6251863 (2001-06-01), Yue
patent: 6436448 (2002-08-01), Yue
patent: 2002/0022593 (2002-02-01), Yue
patent: 661 662 (1984-04-01), None
patent: 0 107 782 (1984-09-01), None
patent: 0 251 615 (1998-01-01), None
patent: WO 90/13659 (1990-11-01), None
patent: WO 94/29452 (1994-12-01), None
patent: WO 95/00645 (1995-01-01), None
patent: WO 95/07711 (1995-03-01), None
patent: WO 96/41167 (1996-12-01), None
patent: WO 97/16549 (1997-05-01), None
patent: WO 99/40929 (1999-08-01), None
Bell et al., “A Randomized, Double-Blind Placebo-Controlled Trial of the Saftey of Vaginal Recombinant Human Relaxin for Cervical Ripening,”Obstet. Gynecol.82:328-33 (1993).
Ben-Hur et al., “Localization of estrogen receptors in long bones and vertebrae of human fetuses,”Calcif. Tiss. Int.53:91-96 (1993).
Bibby, “Orthotopic Models of Cancer for Preclinical Drug Evaluation: Advantages and Disadvantages,”European J. Cancer40:852-857 (2004).
Bryant-Greenwood et al., “Human Relaxins: Chemistry and Biology,”Endocr. Rev.15:5-26 (1994).
Bryant-Greenwood et al., “Sequential Appearance of Relaxin, Prolactin and IGFBP-1 During Growth and Differentiation of the Human Endometrium,”Mol. Cell. Endocrinol.95:23-29 (1993).
Bullesbach et al., “The Receptor-Binding Site of Human Relaxin II. A Dual Prong-Binding Mechanism,”J. Biol. Chem.267:22957-60 (1992).
Burgess et al., “Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue,”J. Cell Biol.111:2129-2138 (1990).
Chen et al., “The Pharmacokinetics of Recombinant Human Relaxin in Nonpregnant Women After Intravenous, Intravaginal, and Intracervical Administration,”Pharm. Res.10:834-38 (1993).
Colon et al., “Relaxin Secretion into Human Semen is Independent of Gonadotropin Stimulation,”Biol. Reprod.50:187-92 (1994).
Dennis, “Off By a Whisker,”Cancer News442:739-741 (2006).
Golub et al., “Effect of Short-Term Infusion of Recombinant Human Relaxin on Blood Pressure in the Late-Pregnant Rhesus Macaque (Macaca Mulatta),”Obstet. Gynecol.83:85-88 (1994).
Guo, “Protein Tolerance to Random Amino Acid Change,”PNAS101:9205-9210 (2004).
Gura, “Systems for Identifying New Drugs are Often Faulty,”Science278:1041-1042 (1997).
Hagemann et al., “Relaxin Enhances In Vitro Invasiveness of Breast Cancer Cell Lines and Expression of Matrix Metalloproteases,”Oncology23:156 (2000).
Hall et al., “Influence of Ovarian Steroids on Relaxin-Induced Uterine Growth in Ovariectomized Gilts,”Endocrinology130:3159-66 (1992).
Hansell et al., “The Role of Relaxin in Promoting Prostate Cancer Cellular Motility and Wound Healing,”Breast And Prostate Cancer IISupplement 0(18D), p. 230, abstract Y11O (1994).
Huang et al., “Stimulation of Collagen Secretion by Relaxin and Effect of Oestrogen on Relaxin Binding in Uterine Cervical Cells of Pigs,”J. Reprod. Fert.98:153-58 (1993).
Jauniaux et al., “The Role of Relaxin in the Development of the Uteroplacental Circulation in Early Pregnancy,”Obstet. Gynecol.84:338-342 (1994).
Johnson et al., “Relationship Between Ovarian Steroids, Gonadotrophins and Relaxin During the Menstrual Cycle,”J. Endocrinol.129:121-5 (1993).
Johnson et al., “The Regulation of Plasma Relaxin Levels During Human Pregnancy,”J. Endocrinol.142:261-5 (1994).
Kelland, “‘Of Mice and Men’”: Values and Liabilities of the Athymic Nude Mouse Model in Anticancer Drug Development,European J. Cancer40:827-836 (2004).
Kibblewhite et al., “The Effect of Relaxin on Tissue Expansion,”Arch. Otolarynogol. Head Neck Surg.118:153-56 (1992).
Krajewski et al., “Immunohistochemical Determination of In Vivo Distribution of Bax, a Dominant Inhibitor of Bcl-2,”Am. J. Pathol.145:1323-1336 (1994).
Lane et al., “Decidualization of Human Endometrial Stromal Cells in Vitro: Effects of Progestin and Relaxin on the Ultrastructure and Production of Decidual Secretory Proteins,”Human Reprod.9:259-66 (1994).
Lanzafame et al., “Pharmacological Stimulation of Sperm Motility,”Human Reprod.9:192-9 (1994).
Lazar et al., “Transforming Growth Factor α: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities,”Mol. Cell. Biol.8:1247-1252 (1988).
Lee et al., “Monoclonal Antibodies Specific for Rat Relaxin. VI. Passive Immunization with Monoclonal Antibodies throughout the Second Half of Pregnancy Disrupts Histological Changes Associated with Cervical Softening at Parturition in Rats,”Endocrinology130:2386-91 (1992).
Luque et al., “A Highly Conserved Arginine Is Critical for the Functional Folding of Inhibitor of Apoptosis (IAP) BIR Domains,”Biochemistry41:13663-13671 (2002).
MacLennan et al., “Ripening of the Human Cervix and Induction of Labor with Intracervical Purified Porcine Relaxin,”Ostet. Gynecol.68:598-601 (1986).
Neuberger et al., “Recombinant Antibodies Prossessing Novel Effector Functions,”Nature312:604-608 (1984).
O'Day-Bowman et al., “Hormonal Control of the Cervix in Pregnant Gilts. III. Influence on Cervical Biochemical Properties in Ovariectomized Hormone-Treated Pregnant Gilts,”Endocrinology129:1967-76 (1991).
Palejawala et al., “Demonstration of a Relaxin Receptor and Relaxin-Stimulated Tyrosine Phosphorylation in Human Lower Uterine Segment Fibroblasts,”Endocrinology139:1208-12 (1998).
Park et al., “Effects of Relaxin on the Fertilization Capacity of Human Spermatozoa,”Am. J. Obstet. Gynecol.158:974-979 (1988).
Petersen et al., “Normal Serum Relaxin in Women with Disagling Pelvic Pain During Pregnancy,”Gynecol. Obstet. Invest.38:21-23 (1994).
Peterson and Houghton, “Integrating Pharmacology and in vivo Cancer Models in Preclinical and Clinical Drug Development,”European J. Cancer40:837-844 (2004).
Saijo, “What are the Reasons for Negative Phase III Trials of Molecular-Target-Based Drugs?”Cancer Sci.95:772-776 (2004).
Poisner et al., “Relaxin Stimulates the Synthesis and Release of Prorenin From Human Decidual Cells: Evidence of Autocrine/Paracrine Regulation,”J. Clin. Endocrinol. Metab.70:1765-67 (1990).
Saiki et al., “Premier-Directed Enzymatic Amplification of DNA with a Thermostable DNA Polymerase,”Science239:487-91 (1988).
Saugstad, “Is Persistent Pelvic Pain and Pelvic Joint Instability Associated with Early Menarche and with Oral Contraceptives?,”Eur. J. Obstet. Gynecol. Reprod. Biol.41:203-206 (1991).
Saxena et al., “Is the Relaxin System a Target for Drug Development? Cardiac Effects of Relaxi
Amento Edward P.
Samuel Chrishan S.
Christensen O'Connor Johnson & Kindness PLLC
Molecular Medicine Research Institute
Rawlings Stephen L
LandOfFree
Methods of modulating apoptosis by administration of relaxin... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of modulating apoptosis by administration of relaxin..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of modulating apoptosis by administration of relaxin... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4157133